Bovie Medical Corporation Announces Appointment of Laura Iversen as Director of Global Operations for Advanced Energy
22 10월 2018 - 8:30PM
Business Wire
Bovie Medical Corporation (NYSEMKT:BVX) (the “Company”),
a medical technology company and the developer of J-Plasma®, a
patented surgical product marketed and sold under the Renuvion™
Cosmetic Technology brand in the cosmetic surgery market, today
announced the appointment of Laura Iversen as Director of Global
Operations for Advanced Energy.
“Bovie Medical is pleased to announce the appointment of Laura
Iversen to this newly created leadership position, as we continue
to focus on improving our manufacturing capabilities and
efficiencies to accommodate the strong demand that we anticipate
for our Advanced Energy products in the years to come,” said
Charlie Goodwin, Chief Executive Officer of the Company. “Ms.
Iversen will be responsible for all aspects pertaining to the
operations and manufacturing of our Advanced Energy portfolio. With
a strong background that includes over 15 years of management
experience in the manufacturing industry, including significant
expertise in the medical device sector specifically, we believe
that she is the ideal candidate for this position and look forward
to her contributions.”
Prior to joining Bovie Medical, Ms. Iversen was the Director of
Manufacturing and Lean Leader for Orluck Industries, Inc., a
precision manufacturer of critical components in the Aerospace,
Medical and other industries, where she oversaw the Manufacturing,
Engineering, and Quality Departments. Ms. Iversen’s career
highlights also include four years of experience, from 2012 until
2016, as the Director of Business Systems & Operational
Excellence Champion for Cretex Companies, Inc., diversified family
of manufacturing companies serving the Medical, Aerospace &
Defense, Infrastructure, and Industrial markets. From 2007 until
2012, Ms. Iversen was the Manager and later Director of Business
Systems for Ultra Machining Company (“UMC”), a premiere
manufacturer of complex, precision machined parts and assemblies
for customers across the Medical, Aerospace, Commercial, Energy and
Industrial markets. From 2002 until 2007, Ms. Iversen served in
several roles of increasing responsibility for Gyrus ACMI, a
manufacturer of surgical devices, culminating in her promotion to
Director of Materials in 2005. Ms. Iversen began her career in 1992
as a Buyer and Planner for Digi International Inc. (NASDAQ: DGII),
a leading global provider of business and mission-critical and
Internet of Things connectivity products and services.
About Bovie Medical
Corporation:
Bovie Medical Corporation is a medical technology company and
the developer of J-Plasma® (marketed and sold under the Renuvion™
Cosmetic Technology brand in the cosmetic surgery market), a
patented plasma-based surgical product for cutting, coagulation and
ablation of soft tissue. J-Plasma technology utilizes a helium
ionization process to produce a stable, focused beam of plasma that
provides surgeons with greater precision, and minimal invasiveness.
The Company also leverages its expertise through original equipment
manufacturing (OEM) agreements with other medical device
manufacturers. For further information about the Company and its
products, please refer to the Bovie Medical Corporation website at
www.boviemedical.com.
Cautionary Statement on Forward-Looking
Statements:
Certain matters discussed in this release and oral statements
made from time to time by representatives of the Company may
constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 and the Federal
securities laws. Although the Company believes that the
expectations reflected in such forward-looking statements are based
upon reasonable assumptions, it can give no assurance that its
expectations will be achieved.
Forward-looking information is subject to certain risks, trends
and uncertainties that could cause actual results to differ
materially from those projected. Many of these factors are beyond
the Company's ability to control or predict. Important factors that
may cause actual results to differ materially and that could impact
the Company and the statements contained in this release can be
found in the Company's filings with the Securities and Exchange
Commission including the Company's Report on Form 10-K for the year
ended December 31, 2017 and subsequent Form 10-Q filings. For
forward-looking statements in this release, the Company claims the
protection of the safe harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of 1995.
The Company assumes no obligation to update or supplement any
forward-looking statements whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181022005064/en/
Investor Relations
Contact:Westwicke Partners on behalf of Bovie
Medical CorporationMike Piccinino,
CFA443-213-0500investor.relations@boviemed.com
Bovie (AMEX:BVX)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Bovie (AMEX:BVX)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024